Executive Summary
While international headlines remain fixated on China’s property slump, a quiet but profound revolution is reshaping the national economy. In 2025, China’s pharmaceutical and medical device sector definitively pivoted from a volume-driven domestic industry to a global innovation powerhouse. With a record $135 billion in out-licensing deals signed last year alone, Chinese biotech firms are no longer just manufacturing generics or biosimilars; they are exporting first-in-class innovation to the world’s most regulated markets. This shift represents a strategic maturity that European investors and policymakers can no longer afford to overlook, as Chinese firms now supply the very innovation pipelines that Western giants depend on.
Figure 1: China's accelerating biopharma innovation engine and global integration.
The Great Pivot: A $2.3 Trillion Opportunity
The Chinese healthcare market is projected to reach approximately $2.3 trillion (16 trillion RMB) by 2030. This explosive growth is not merely a function of GDP but a demographic inevitability. By 2035, China’s population aged 60 and above will exceed 400 million, nearly the entire population of the European Union.
This demographic pressure has forced Beijing to treat healthcare not just as a social service, but as a strategic economic pillar. The Healthy China 2030 initiative has effectively channeled state resources into industrial clusters in Jiangsu, Shanghai, and the Greater Bay Area, creating integrated ecosystems where academic research, clinical trials, and manufacturing coexist.
Unlike the internet sector, which focused on consumer applications and soft tech, this new wave of growth is “hard tech” deep science. Chinese firms are leveraging their massive patient data pools to accelerate drug discovery in oncology, immunology, and metabolic diseases. The result is a hyper-efficient R&D engine capable of producing assets that Western companies are eager to buy.
Innovation Over Imitation: The 2025 Deal Surge
The year 2025 will be remembered as the inflection point where Chinese biotech went global at scale. Out-licensing deals – where Chinese firms sell the rights to their drugs to foreign partners – surged to an estimated $135 billion in total potential value. This figure represents a massive leap from previous years, driven by European and American pharmaceutical firms seeking to replenish their drying pipelines with high-quality, clinically validated assets from China.
Several landmark transactions highlight this trend:
Merck & LaNova Medicines
Merck committed $588 million upfront (with up to $2.7 billion in milestones) for LaNova’s novel cancer drug LM-299. This deal signals that despite geopolitical rhetoric, US giants remain deeply intertwined with Chinese innovation, unable to ignore the commercial potential of these assets.
Pfizer & 3SBio
In a record-setting transaction, Pfizer committed up to $6 billion for rights outside China to 3SBio’s PD-1/VEGF bispecific antibody, including a massive $1.25 billion upfront payment. This stands as the largest upfront payment ever for a Chinese-origin therapy, reflecting the intense competition for top-tier Chinese assets.
Takeda & Innovent Biologics
In a deal worth up to $1.2 billion upfront and potentially exceeding $11 billion with milestones, Japanese pharma giant Takeda licensed global rights (excluding China) to Innovent’s colorectal cancer asset (IBI363). This validation from a conservative global player underscores that Innovent’s platform is now viewed as best-in-class.
BioNTech & Biotheus
Moving beyond partnerships, German mRNA pioneer BioNTech moved to acquire Chinese firm Biotheus outright in a deal valued at $800 million upfront, securing a promising PD-L1/VEGF bispecific antibody (BNT327/PM8002). This acquisition is particularly significant as it demonstrates how European firms are integrating Chinese innovation directly into their core portfolios to challenge incumbents like Merck.
These acquisitions are not for derivative compounds; rather, they target novel assets with the potential to redefine standard-of-care protocols. They are for novel mechanisms of action, particularly in Antibody-Drug Conjugates (ADCs) and bispecific antibodies, areas where China has arguably taken a global lead in development speed and clinical data generation.
The GLP-1 Frontier: The Next Battleground
Beyond oncology, the metabolic space is emerging as a critical front. While Novo Nordisk and Eli Lilly dominate the global obesity market, Chinese firms are rapidly catching up with next-generation candidates.
Corxel Pharmaceuticals, for instance, secured $287 million in Series D1 financing in early 2026 to bankroll its oral GLP-1 pill, CX11, which is entering Phase II trials in the US. This direct challenge to Western incumbents in their home markets signifies a new level of ambition. Additionally, Sciwind Biosciences licensed its GLP-1 analogue ecnoglutide to US-based Verdiva Bio for $70 million upfront and over $2.4 billion in milestones, further integrating Chinese metabolic innovation into the global supply chain. The sheer scale of China’s domestic diabetes population provides a clinical trial advantage that allows these firms to generate data faster and cheaper than their Western peers.
The Global Regulatory Bridge: Cracking the EMA and FDA
Historically, Chinese drugs struggled to gain approval in the US and EU due to data quality concerns. That era is ending. In 2025, Chinese firms achieved breakthrough successes with the European Medicines Agency (EMA) and the US FDA, proving they can navigate the world’s toughest regulatory environments.
Figure 2: Clinical trial platforms and specialized biopharma R&D systems.
Shanghai Henlius Biotech: The Globalization Blueprint
Henlius Biotech (2696.HK) represents the successful transition from a local biosimilar player to a global innovative powerhouse. By the end of 2025, Henlius proved that a Chinese firm could not only develop high-quality biologics but also master the complex European regulatory landscape without relying solely on Western intermediaries.
According to Shanghai Stock Exchange filings and EMA records, the Henlius strategic breakthrough centered on serplulimab, its proprietary anti-PD-1 antibody. While many Chinese peers sought US approval first, Henlius targeted the European Union. In early 2025, the European Commission granted marketing authorization for serplulimab for the treatment of small cell lung cancer (ES-SCLC), marking a historic first for a Chinese-developed anti-PD-1 in the EU market.
The Henlius business model is defined by a “Dual-Wheel” strategy: leveraging high-volume biosimilar sales (such as Hanquyou, its trastuzumab biosimilar) to fund high-risk innovative R&D. Data from the National Medical Products Administration (NMPA) shows that Henlius has maintained an R&D-to-revenue ratio exceeding 30% over the last three fiscal years, a figure comparable to leading Swiss and German pharmaceutical firms.
For European decision-makers, the Henlius case offers three key lessons: First, the speed of clinical iteration in China is significantly faster due to the scale of patient enrollment. Second, Chinese firms are increasingly willing to build their own commercial infrastructure in Europe rather than just licensing assets out. Third, regulatory harmonization (ICH standards) has effectively removed the “quality discount” once applied to Chinese clinical data.
State Support and Industrial Policy
This success is not accidental; it is the result of deliberate industrial policy. The Chinese government has systematically de-risked the sector through:
- Cluster Development: Creating “Bio-Bays” in Shanghai (Zhangjiang), Suzhou, and Beijing that offer subsidized rent, shared labs, and tax incentives.
- Talent Attraction: Aggressive programs to lure Chinese scientists back from Pfizer, Merck, and academic institutions in the US and UK.
- Capital Market Reform: Allowing pre-revenue biotech companies to list on the Hong Kong Stock Exchange (Chapter 18A) and the Shanghai STAR Market, providing a crucial exit route for venture capital.
This state support has allowed Chinese firms to “fail fast” and iterate quickly, creating a Darwinian environment where only the most robust molecules survive to reach the global stage.
Strategic Risks: Forced Decoupling
Despite the optimism, significant storm clouds are gathering. The integration of Chinese biotech into Western supply chains has triggered alarm bells in Washington.
The BIOSECURE Act, signed into US law as part of the FY2026 National Defense Authorization Act (NDAA) on December 18, 2025, designates certain Chinese biotechnology companies as “companies of concern.” The legislation restricts these companies’ access to US federal contracts and funding. While the final version included grandfathering clauses and delayed effective dates (prohibitions likely taking effect in 2026 or 2027) to prevent immediate supply chain chaos, the message is clear: the US government views biotech as a national security asset, similar to semiconductors.
For European investors, this creates a complex dilemma. On one hand, Chinese innovation is abundant and attractively priced. On the other, the risk of secondary sanctions or forced decoupling remains real. European pharma majors like AstraZeneca and Sanofi are betting that the commercial logic of life-saving innovation will trump geopolitical friction. However, they are also quietly diversifying their supply chains to mitigate “China risk,” leading to a “China for China, plus export” model where global supply chains are increasingly bifurcated.
China Biopharma Strategic Deals and Regulatory Milestones
2024-2026 Overview
| Date | Entity Name | Partner/Acquirer | Deal Type | Asset/Indication | Upfront Payment (USD) | Total Potential Value (USD) | Key Milestone/Regulatory Status | Source |
|---|---|---|---|---|---|---|---|---|
| July 2025 | Jiangsu Hengrui | GSK | Licensing | Oncology programmes (approx. 12) | Not in source | $12,000,000,000 | Broad strategic alliance covering oncology portfolio. | 1 |
| October 21, 2025 | Innovent Biologics | Takeda | Licensing | IBI363 (PD-1/IL-2 α fusion) & IBI343 (Claudin 18.2 ADC) / Oncology | $1,200,000,000 | $11,000,000,000 | IBI363 granted FDA Fast Track for sqNSCLC; Phase 3 study planned. | 2-4 |
| May 2025 | 3SBio | Pfizer | Licensing | SSGJ-707 (PD-1/VEGF bispecific antibody) / Oncology | $1,250,000,000 | $6,000,000,000 | Record-setting upfront payment for a Chinese-origin therapy. | 1-3 |
| June 2025 | CSPC Pharmaceutical | AstraZeneca | Licensing | AI-driven drug discovery / Oncology | Not in source | $5,000,000,000 | Collaboration centered on AI platform and preclinical cancer candidates. | 1 |
| November 14, 2024 | LaNova Medicines | Merck | Licensing | LM-299 (PD-1/VEGF bispecific antibody) / Oncology | $588,000,000 | $3,288,000,000 | Currently assessed in Phase I study in China for solid tumors. | 2, 3, 5 |
| January 2025 | Sciwind Biosciences | Verdiva Bio | Licensing | ecnoglutide (GLP-1 analogue) / Metabolic Disease | $70,000,000 | $2,470,000,000 | Global rights (ex-Asia) licensed to U.S.-based Verdiva Bio. | 1-3 |
| November 14, 2024 | Biotheus | BioNTech | Acquisition | BNT327/PM8002 (PD-L1/VEGF bispecific antibody) | $800,000,000 | $950,000,000 | Transaction expected to close in Q1 2025. | 2, 3, 5, 6 |
| January 23, 2026 | Corxel Pharmaceuticals | Not in source | Private Financing | CX11 (Oral GLP-1) / Obesity and Type 2 Diabetes | $287,000,000 | $287,000,000 | Proceeds to complete Phase II testing in the U.S. and prepare Phase III. | 2, 3, 7 |
| February 5, 2025 | Shanghai Henlius Biotech | Accord Healthcare (Intas subsidiary) | Licensing | serplulimab (PD-1 inhibitor) / ES-SCLC | Not in source | Not in source | Approved by European Commission; first Chinese anti-PD-1 mAb in EU. | 2, 3, 8 |
| December 18, 2025 | Chinese Biotech Sector | U.S. Federal Government | Regulatory Status | Biotechnology Companies of Concern | Not in source | Not in source | BIOSECURE Act signed into law as part of FY 2026 NDAA. | 2, 3, 9 |
Bibliographic Reference Mapping
| Source No. | Reference Publication / Title |
|---|---|
| 1 | China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus |
| 2 | China’s Pharmaceutical Ascent: A Novel Global Growth Engine |
| 3 | China’s Pharmaceutical Global Ascent – China’s Pharmaceutical Global Ascent |
| 4 | Takeda Announces Oncology Partnership with Innovent |
| 5 | Merck Hops Onto PD-1/VEGF Train, Committing up to $3B Plus in LaNova Deal – BioSpace |
| 6 | Goodwin Advises Biotheus in Agreement to be Acquired by BioNTech for $800 Million Upfront and $150 Million in Milestones |
| 7 | China’s Corxel Nabs $287M Series D1 to Bankroll GLP-1 Pill – BioSpace |
| 8 | Henlius’ Serplulimab Becomes EU’s First Anti PD-1 mAb Approved for ES-SCLC | Pearce IP |
| 9 | BIOSECURE Act Update (Morrison Foerster Legal Update) |
Conclusion
China’s pharmaceutical rise is structural, not cyclical. The combination of an aging population, state-backed industrial policy, and a maturing innovation ecosystem has created a juggernaut that is now spilling over borders. For European stakeholders, the window to treat China merely as a raw material supplier has closed. The new reality is one of complex interdependence, where China is simultaneously a fierce competitor, a critical partner, and a vital source of medical innovation. As the “Bio-Chip” war heats up, the ability to navigate this landscape, balancing access to innovation with geopolitical risk, will define the winners in the next decade of global healthcare.